These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9076482)

  • 21. Bropirimine in bladder cancer: clinical studies.
    Sarosdy MF
    Ann N Y Acad Sci; 1993 Jun; 685():301-8. PubMed ID: 8363234
    [No Abstract]   [Full Text] [Related]  

  • 22. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
    Tomisaki I; Kubo T; Minato A; Fujimoto N
    Cancer Invest; 2018 Feb; 36(2):152-157. PubMed ID: 29393701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
    BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients.
    Katims AB; Tam AW; Rosen DC; Zampini AM; Atallah W; Mehrazin R; Gupta M
    Urol Oncol; 2021 Apr; 39(4):234.e9-234.e13. PubMed ID: 32958446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
    Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
    Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
    Kaasinen E; Wijkström H; Rintala E; Mestad O; Jahnson S; Malmström PU
    Scand J Urol; 2016 Oct; 50(5):360-8. PubMed ID: 27603424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
    Brandau S
    J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter.
    Irie A; Iwamura M; Kadowaki K; Ohkawa A; Uchida T; Baba S
    Urology; 2002 Jan; 59(1):53-7. PubMed ID: 11796281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
    Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
    J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder.
    Hara I; Yao A; Muramaki M; Hikosaka S; Yamada Y; Kawabata G; Kamidono S
    Int J Urol; 2004 Apr; 11(4):250-2. PubMed ID: 15028107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
    Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
    J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
    Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
    Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
    Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
    Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.